Are 2 doses of aspirin effective at preventing ASCVD?
Two aspirin doses may be safe and effective at atherosclerotic cardiovascular disease secondary prevention.
In a study published in JAMA Cardiology, researchers randomly assigned 15,076 patients with a median age of 67.6 years — 10,352 of whom were male and 4,724 of whom were female — to receive either 81 or 325 milligrams of aspirin daily in secondary prevention of ASCVD events.
The researchers found there were no statistically significant sex-specific differences in safety and efficacy outcomes between the 81- and 325-milligram dose groups. Although the female patients had a higher risk of hospitalization, they had a lower rate of revascularization procedures compared with the male patients.
However, the patients in the 325-milligram dose group were more likely to switch or discontinue their doses compared with those in the 81-milligram dose group.
The findings supported the continued use of aspirin as a cornerstone therapy in the secondary prevention of ASCVD events.
Read more: JAMA Cardiology
The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.